Roche Secures Global Rights to Hanmi’s Muscle-Sparing Obesity Drug in $2.3B Deal

Key points

• Genentech will pay $190 million upfront, with total deal value reaching $2.3 billion including milestones and royalties.
• HM17321 is a UCN2 analog currently in Phase 1 trials, with Hanmi completing the study before Genentech takes over Phase 2.
• The drug targets obesity, type 2 diabetes, and cardiovascular diseases, excluding South Korea from the licensing rights.
• Hanmi shares jumped 30% following the announcement, reflecting market confidence in the asset’s potential.
• Preclinical data showed weight loss as a monotherapy and in combination with GLP-1 drugs, without the lean mass loss typical of incretins.

Background

Roche has aggressively expanded its obesity portfolio, aiming to become a top-three player in the weight loss space. This follows previous partnerships with Zealand Pharma and Carmot, and internal efforts like the anti-myostatin antibody emugrobart. The broader industry is shifting focus from simple weight reduction to improving body composition, as highlighted by recent research on muscle-preserving mechanisms and the economic impact of GLP-1 drugs on bariatric surgery rates.

How outlets are covering it

Fierce Biotech emphasizes the strategic risk-taking by Roche, noting that the UCN2 mechanism was previously explored and scrapped by Eli Lilly in 2019 for heart failure. Hanmi’s press release, cited by PR Newswire, frames HM17321 as a 'first-in-class' therapy that addresses the 'paradigm shift' toward metabolic health and body composition. Investing.com highlights the immediate market reaction, with Hanmi’s stock surging 30%, signaling strong investor confidence in the deal’s value. While all sources agree on the financial terms and mechanism, Fierce Biotech provides deeper context on Roche’s broader pipeline, whereas the press release focuses on the scientific differentiation from GLP-1s.

Why it matters

This deal signals a major shift in obesity treatment strategy, moving beyond GLP-1 agonists that often cause muscle loss. By securing a non-incretin asset, Roche diversifies its pipeline and addresses a critical unmet need in preserving lean mass, potentially capturing a larger share of the cardiometabolic market. The $2.3 billion valuation underscores the high stakes and competitive intensity in the next generation of weight loss therapies.

What to watch

Hanmi will complete the ongoing Phase 1 trial in healthy volunteers and individuals with obesity. Genentech is expected to take over development for Phase 2 trials, exploring HM17321 for obesity, type 2 diabetes, and cardiovascular conditions. The market will watch for early efficacy and safety data to validate the muscle-preserving claims.